UBS O'Connor’s Theseus Pharmaceuticals, Inc. Common Stock THRX Stock Holding History

UBS O'Connor’s Portfolio THRX Stock Details THRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q1	–	Sell	-12,517	Closed	-$50.7K	–	636
2023 Q4	$50.7K	Sell	12,517 -168,935	-93%	-$515K	﹤0.01%	426
2023 Q3	$488K	Buy	181,452 +60,000	+49%	+$235K	0.01%	403
2023 Q2	$1.13M	Buy	121,452 +10,737	+10%	+$106K	0.02%	371
2023 Q1	$983K	Buy	+110,715	New	+$1.09M	0.02%	405

UBS O'Connor's THRX Position: Q1 2024 in Review

UBS O'Connor sold out of Theseus Pharmaceuticals, Inc. Common Stock (THRX) in Q1 2024, closing a stake of 12,517 shares — an estimated $50.7K sold.

UBS O'Connor first reported a position in THRX in Q1 2023 and held it in 4 quarters. The position peaked at $1.13M in Q2 2023. 1 fund tracked by Wall St. Rank holds THRX as of Q1 2024.

UBS O'Connor reported no remaining Theseus Pharmaceuticals, Inc. Common Stock position as of Q1 2024 after selling out during the quarter.
UBS O'Connor sold 12,517 Theseus Pharmaceuticals, Inc. Common Stock shares in Q1 2024, an estimated $50.7K.
UBS O'Connor first reported a position in Theseus Pharmaceuticals, Inc. Common Stock in Q1 2023 and held it in 4 quarters.
UBS O'Connor's Theseus Pharmaceuticals, Inc. Common Stock position peaked at $1.13M in Q2 2023.
1 fund tracked by Wall St. Rank held Theseus Pharmaceuticals, Inc. Common Stock as of Q1 2024.

Based on UBS O'Connor's 13F filing for Q1 2024, filed 15 May 2024.